Cambridge, MA
Posted 4 weeks ago

The Scientist will design experiments, driven to support assay development. You will bring your expertise to a scientific team working on gene therapy by developing state-of-the-art therapies for the treatment of rare inherited diseases. Our research is in the field of ex vivo lentiviral vector gene transfer into hematopoietic stem/progenitor cells with a mission of curing lysosomal storage disorders and rare diseases in one dose. You will assist in all aspects of research to test gene therapy vectors for functionality.

Key Responsibilities:

  • Be actively involved in designing experiments, supporting assay development.
  • Assist in the decision-making processes for the studies.
  • Communicate cross-functionally across different groups.
  • Actively participate as a leader in team settings including scientific progress meetings.
  • Present data concisely both internally and at conferences.
  • Maintain current knowledge of industry literature related to our studies.
  • Work with CRO’s to ensure good communication and solid documentation.
  • Partner with Finance to maintain and track budget.
  • Publish scientific data.

Minimum Requirements/Qualifications:

  • Requires a PhD in molecular or cell biology or gene therapy field with a minimum of two years+ of related industry experience.
  • Demonstrated expertise with techniques including qPCR, Western blotting, ELISAs, molecular cloning, lentiviral vectors, and hematopoietic stem cell culture is preferred.
  • Previous experience performing (mouse) experiments required.
  • Excellent communication and presentation skills
  • Demonstrated ability working successfully in team environment.
  • Documentation of all work required

To apply, email your resume to:
AVROBIO, Inc is an EEO employer

About AVRO
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its gene therapy candidate, AVR‑RD‑01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, Cystinosis and Pompe disease. AVROBIO’s lentiviral platform has broad potential for other rare and non-rare genetic diseases. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.

Apply Online